September 1, 2016
Pfizer said on August 31 that it has filed an application in Japan, seeking an additional indication for its cancer drug Xalkori (crizotinib) for ROS1 fusion gene-positive unresectable, advanced/recurrent non-small cell lung cancer (NSCLC). In Japan, Xalkori was approved in...read more